US economy: Mixed labour and inflation picture – NBC Economics and Strategy
NBC Economics and Strategy highlights that U.S. nonfarm payrolls rose just 29K in September versus a 90K consensus, while the household survey showed a 406K employment surge and a 4.2% unemployment rate. Q2 real GDP was revised up to 2.2% annualized. The headline PCE deflator stayed at 3.4% and core at 3.0%, both below expectations due partly to methodology changes.
Soft payrolls and benign PCE
"In the U.S., nonfarm payrolls rose 29K in September, a weaker print than the one anticipated by economists polled by Bloomberg (+90K)."
"Released at the same time, the household survey painted a more upbeat picture of the situation prevailing in the labour market, as it showed employment surging 406K in September."
"Despite the increase in employment in September, the unemployment rate rose by one tenth of a percentage point to 4.2%."
"Still in the U.S., data released this week by the Bureau of Economic Analysis showed an upward revision to Q2 real GDP growth in the third estimate, from 1.5% to 2.2% on an annualized basis, a print higher than the consensus, which had predicted no revision."
"The headline PCE deflator in the U.S. printed at 3.4% in August, unchanged from the prior month and significantly below consensus expectations (3.7%). The 12-month core measure also stayed unchanged, at 3.0%. Once again, this result was three-tenths lower than economists' expectations. It should be noted that part of the negative surprise in the inflation data was due to a change in methodology."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Applied Digital shares surge as Q1 revenue quadruples
October 8 - ** Data center service provider Applied Digital (APLD.O) saw its stock rise 3.57% in pre-market trading to $24.66 ** The company’s Q1 revenue (link) surged more than fourfold to $341.9 millions, far surpassing analyst estimates of $133.8 millions ** Northland Capital Securities noted that APLD’s revenue and cash flow should increase significantly in the coming years as contracted data center capacity becomes operational and starts generating income ** Net loss attributable to common shareholders widened from $18.5 millions (7 cents/share) a year ago to $221 millions (76 cents/share) ** According to data compiled by London Stock Exchange Group (LSEG), the average rating from 17 analysts covering the stock is “Buy”, with a median target price of $70.00, representing an upside of about 194% from the current price ** Year-to-date, the stock is down about 2.9%, while the Nasdaq Index .IXIC is up 18.5% over the same period. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation and provides it only as a convenience. Reuters assumes no liability for any damage or loss resulting from the use of automated translation.)
WTI crude oil rises above $91 per barrel, up 3.02% intraday
WTI crude oil rose above $91 per barrel for the first time since October 2, with a daily increase of 3.02%.
AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) TROP2 ADC receives approval for new indication in China
According to information from Zhihu Finance APP, AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) have announced that Datroway® (generic name: datopotamab deruxtecan for injection) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not suitable for PD-1/PD-L1 inhibitor therapies. Datopotamab deruxtecan is an antibody-drug conjugate (ADC) targeting TROP2, developed with proprietary technology by Daiichi Sankyo, and jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Abu Dhabi National Oil Company invites bids for crude oil cargo shipments
Trader: Abu Dhabi National Oil Company issued a tender this week to sell crude oil for December loading or January delivery.
Crypto prices
More
